Form 483

Azurity Pharmaceuticals, Inc. Form 483, 2022-02-24

FDA issued a Form 483 to Azurity Pharmaceuticals, Inc. on 2022-02-24 with 3 public-safe observations.

483· Form 483 issuedHuman Drugs3 observations

Azurity Pharmaceuticals, Inc. · Woburn, United States · Issued February 24, 2022

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

24 Feb 2022
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by Erik W Koester, Terry Bridgewater

24 Feb 2022
21 CFR 211.67(b)(5)

Cleaning SOPs/equipment protection

Cited by Erik W Koester, Terry Bridgewater

24 Feb 2022
21 CFR 211.84(c)(4)

Top/Middle/Bottom container sampling

Cited by Erik W Koester, Terry Bridgewater

Inspected site

APAzurity Pharmaceuticals, Inc.Woburn, United States

Inspection team

TBTerry Bridgewater

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)(5)Cited across public-safe Form 483 observations1x
21 CFR 211.84(c)(4)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere